Zealand Pharma - Transactions related to share buy-back program (week 37, 2026)

Zealand Pharma repurchased 254,000 shares for DKK 73.9 million during September 7-11 under its up-to-DKK 1.3 billion buyback program. Total purchases have reached 3.30 million shares for DKK 998.3 million, leaving roughly DKK 301.7 million of authorized capacity before the program's October 31, 2026 deadline. Treasury shares now total 4.17 million, or 5.82% of share capital.

Analysis

The relevant signal is mechanical rather than fundamental: ZEAL's remaining authorization is roughly DKK302m with less than seven weeks until expiration. At the recent purchase pace, the program is unlikely to deploy all remaining capacity unless daily participation rises materially; that creates a near-term liquidity bid but does not establish a valuation floor once the program ends. The declining execution prices during the week suggest the broker has been absorbing supply rather than signaling incremental fundamental demand.

Treasury holdings near 5.8% modestly improve per-share economics and reduce free float, potentially amplifying volatility around obesity-drug clinical updates. The more important second-order issue is capital allocation: further repurchases only add value if management's internal estimate of pipeline risk-adjusted NPV materially exceeds the cash retained for late-stage trial costs and commercial buildout. Without updated cash runway, trial-budget, and dilution guidance, the announcement is not sufficient evidence for a fundamental long.

For the next 1-3 months, buyback completion is a negative technical catalyst if no clinical, partnering, or regulatory event replaces the daily demand. Over 6-18 months, ZEAL will trade primarily on differentiation versus Novo Nordisk (NVO) and Eli Lilly (LLY) in obesity, not on a roughly 4-5% potential reduction in shares outstanding. Contrarian view: investors may over-credit the authorization as support; an accelerated buyback into weakness could instead be read as management defending the equity ahead of financing needs, particularly if cash-burn guidance deteriorates.

Danske Bank's role is fee-related and immaterial to group earnings; DANSKE is not a trade expression. Monitor ZEAL's disclosed daily repurchase volume, cash balance, quarterly operating cash burn, and any revision to pivotal-study timelines. The thesis of a temporary support bid is falsified if the program is completed early at rising prices alongside independently positive clinical or partnership news.

Key Decisions for Investors

• No new fundamental ZEAL position solely on this disclosure; treat the residual DKK302m authorization as a tactical support factor through October 31, not an earnings catalyst.
• For existing ZEAL longs, maintain exposure only through defined clinical/partnering catalysts and reduce 25-50% into strength before program expiry if no new fundamental catalyst emerges; loss of the broker bid is the near-term risk.
• Set an alert for a material acceleration in ZEAL daily repurchases versus the recent weekly run rate, coupled with updated cash-runway disclosure. A completion trajectory before October 31 without increased financing risk would support a short-dated tactical long; absent those data, remain neutral.
• If ZEAL underperforms NVO and LLY materially after the buyback ends while cash runway and late-stage timelines remain intact, evaluate a 3-6 month long ZEAL / short XBI pair rather than outright beta exposure; exit on trial-delay guidance or cash-burn materially above prior expectations.